rosiglitazone has been researched along with Follicular Thyroid Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andò, S; Aquila, S; Belmonte, M; Bonofiglio, D; Catalano, S; Gabriele, S; Qi, H | 1 |
| Fröhlich, E; Machicao, F; Wahl, R | 1 |
2 other study(ies) available for rosiglitazone and Follicular Thyroid Carcinoma
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor gamma inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner.
Topics: Adenocarcinoma, Follicular; Cell Division; Cell Line, Tumor; Chromatin Immunoprecipitation; Cyclin-Dependent Kinase Inhibitor p21; Electrophoretic Mobility Shift Assay; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Oligonucleotides, Antisense; PPAR gamma; Promoter Regions, Genetic; Rosiglitazone; Signal Transduction; Sp1 Transcription Factor; Thiazolidinediones; Thyroid Neoplasms; Up-Regulation | 2008 |
Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture.
Topics: Adenocarcinoma, Follicular; Animals; Annexin A5; Apoptosis; Cell Differentiation; Cell Line, Transformed; Cell Proliferation; Chromans; Pioglitazone; PPAR gamma; Radiation-Sensitizing Agents; Retinoid X Receptor alpha; RNA, Messenger; Rosiglitazone; Swine; Symporters; Thiazolidinediones; Thyroglobulin; Thyroid Gland; Thyroid Neoplasms; Troglitazone | 2005 |